Hospitalizations in patients with idiopathic pulmonary fibrosis.
Interstitial lung disease
Mechanical ventilation
Mortality
Pulmonary fibrosis
Respiratory function tests
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
30 Sep 2021
30 Sep 2021
Historique:
received:
06
05
2021
accepted:
23
09
2021
entrez:
1
10
2021
pubmed:
2
10
2021
medline:
15
2
2022
Statut:
epublish
Résumé
Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF). We investigated the impact of hospitalizations on outcomes in patients with IPF. The IPF-PRO Registry is an observational US registry that enrolled patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months. Associations between patient characteristics and hospitalization, and between hospitalization and mortality, were analyzed using Cox regression models. A total of 1002 patients with IPF were enrolled into the IPF-PRO Registry. Over a median follow-up time of 23.7 months (maximum: 67.0 months), 568 patients (56.7%) had at least one hospitalization. Of these patients, 319 (56.2%) had at least one respiratory-related hospitalization and 120 (21.1%) had at least one hospitalization with ventilatory support. Younger age (HR 0.68 [95% CI 0.55, 0.84] per 5-year increase for patients < 62 years), lower BMI (0.96 [0.93, 0.98] per 1-point increase), lower FVC % predicted (0.90 [0.83, 0.97] per 10% increase), oxygen use at rest (2.85 [2.18, 3.72]) and history of pulmonary hypertension (2.02 [1.37, 2.96]) at enrollment were associated with an increased risk of respiratory-related hospitalization during follow-up. In a multivariable model, there was an eightfold increase in the risk of mortality during hospitalization or within 90 days of discharge compared with outside of this period. The risk of mortality associated with a respiratory hospitalization or a hospitalization with ventilatory support was even greater. Data from the IPF-PRO Registry demonstrate that hospitalizations are common among patients with IPF. The risk of mortality during hospitalization or within 90 days of discharge was high, particularly among patients who were hospitalized for a respiratory cause or received ventilatory support. Trial registration ClinicalTrials.gov, NCT01915511. Registered 5 August 2013, https://clinicaltrials.gov/ct2/show/NCT01915511.
Sections du résumé
BACKGROUND
BACKGROUND
Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF). We investigated the impact of hospitalizations on outcomes in patients with IPF.
METHODS
METHODS
The IPF-PRO Registry is an observational US registry that enrolled patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months. Associations between patient characteristics and hospitalization, and between hospitalization and mortality, were analyzed using Cox regression models.
RESULTS
RESULTS
A total of 1002 patients with IPF were enrolled into the IPF-PRO Registry. Over a median follow-up time of 23.7 months (maximum: 67.0 months), 568 patients (56.7%) had at least one hospitalization. Of these patients, 319 (56.2%) had at least one respiratory-related hospitalization and 120 (21.1%) had at least one hospitalization with ventilatory support. Younger age (HR 0.68 [95% CI 0.55, 0.84] per 5-year increase for patients < 62 years), lower BMI (0.96 [0.93, 0.98] per 1-point increase), lower FVC % predicted (0.90 [0.83, 0.97] per 10% increase), oxygen use at rest (2.85 [2.18, 3.72]) and history of pulmonary hypertension (2.02 [1.37, 2.96]) at enrollment were associated with an increased risk of respiratory-related hospitalization during follow-up. In a multivariable model, there was an eightfold increase in the risk of mortality during hospitalization or within 90 days of discharge compared with outside of this period. The risk of mortality associated with a respiratory hospitalization or a hospitalization with ventilatory support was even greater.
CONCLUSIONS
CONCLUSIONS
Data from the IPF-PRO Registry demonstrate that hospitalizations are common among patients with IPF. The risk of mortality during hospitalization or within 90 days of discharge was high, particularly among patients who were hospitalized for a respiratory cause or received ventilatory support. Trial registration ClinicalTrials.gov, NCT01915511. Registered 5 August 2013, https://clinicaltrials.gov/ct2/show/NCT01915511.
Identifiants
pubmed: 34592998
doi: 10.1186/s12931-021-01851-4
pii: 10.1186/s12931-021-01851-4
pmc: PMC8481759
doi:
Banques de données
ClinicalTrials.gov
['NCT01915511']
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
257Investigateurs
Albert Baker
(A)
Scott Beegle
(S)
John A Belperio
(JA)
Rany Condos
(R)
Francis Cordova
(F)
Daniel A Culver
(DA)
Daniel Dilling
(D)
John Fitzgerald
(J)
Leann Silhan
(L)
Kevin R Flaherty
(KR)
Kevin Gibson
(K)
Mridu Gulati
(M)
Kalpalatha Guntupalli
(K)
Nishant Gupta
(N)
Amy Hajari Case
(A)
David Hotchkin
(D)
Tristan J Huie
(TJ)
Robert J Kaner
(RJ)
Hyun J Kim
(HJ)
Lisa H Lancaster
(LH)
Mark Steele
(M)
Joseph A Lasky
(JA)
Doug Lee
(D)
Timothy Liesching
(T)
Randolph Lipchik
(R)
Jason Lobo
(J)
Tracy R Luckhardt
(TR)
Joao A Andrade
(JA)
Yolanda Mageto
(Y)
Howard Huang
(H)
Prema Menon
(P)
Yolanda Mageto
(Y)
Lake Morrison
(L)
Andrew Namen
(A)
Justin M Oldham
(JM)
Tessy Paul
(T)
David Zhang
(D)
Anna Podolanczuk
(A)
David Lederer
(D)
Nina M Patel
(NM)
Mary Porteous
(M)
Maryl Kreider
(M)
Rishi Raj
(R)
Paul Mohabir
(P)
Murali Ramaswamy
(M)
Tonya Russell
(T)
Paul Sachs
(P)
Zeenat Safdar
(Z)
Shirin Shafazand
(S)
Marilyn Glassberg
(M)
Ather Siddiqi
(A)
Wael Asi
(W)
Barry Sigal
(B)
Mary E Strek
(ME)
Imre Noth
(I)
Sally Suliman
(S)
Jesse Roman
(J)
Jeremy Tabak
(J)
Rajat Walia
(R)
Timothy P M Whelan
(TPM)
Informations de copyright
© 2021. The Author(s).
Références
Ann Am Thorac Soc. 2015 Jul;12(7):981-7
pubmed: 25923447
Lancet Respir Med. 2015 May;3(5):388-96
pubmed: 25890798
Chest. 2015 Jan;147(1):173-179
pubmed: 25188694
Medicine (Baltimore). 2019 May;98(21):e15779
pubmed: 31124970
BMC Pulm Med. 2016 Jan 05;16:2
pubmed: 26732054
Sci Rep. 2020 Sep 24;10(1):15620
pubmed: 32973215
Am J Respir Crit Care Med. 2019 Jul 15;200(2):168-174
pubmed: 31150266
Eur Respir J. 2017 May 19;49(5):
pubmed: 28526798
J Med Econ. 2017 May;20(5):518-524
pubmed: 28092235
Respir Med. 2008 Oct;102(10):1355-9
pubmed: 18635345
PLoS One. 2017 Jan 18;12(1):e0166462
pubmed: 28099456
BMC Pulm Med. 2017 May 22;17(1):84
pubmed: 28532459
Am J Respir Crit Care Med. 2017 Sep 15;196(6):756-761
pubmed: 28471697
BMJ Open Respir Res. 2016 Jan 11;3(1):e000108
pubmed: 26835134
BMJ Open. 2017 Feb 13;7(2):e013156
pubmed: 28193850
Lung. 2019 Dec;197(6):699-707
pubmed: 31541276
Eur Respir J. 2020 Aug 13;56(2):
pubmed: 32381492
BMC Pulm Med. 2020 Nov 7;20(1):289
pubmed: 33160338
Chest. 2016 May;149(5):1205-14
pubmed: 26836940
Respir Res. 2019 May 30;20(1):105
pubmed: 31142314
Medicine (Baltimore). 2020 Nov 20;99(47):e23143
pubmed: 33217820
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
J Manag Care Spec Pharm. 2016 Apr;22(4):414-23
pubmed: 27023695
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753